IP Library › Granted Patent US 12,570,755
Granted Patent B2
US 12,570,755 · App. 18/331,859 · Granted Mar 10, 2026

Anti-CD20 antibody and uses thereof

Inventors: Isabelle Riviere (New York, NY); Ouathek Ouerfelli (New York, NY); Xiuyan Wang (New York, NY); Frances Weis-Garcia (New York, NY)
Assignee: Memorial Sloan Kettering Cancer Center
C07K16/2887A61K40/11A61K40/31A61K40/4221A61P35/00C07K14/7051C07K14/70517C07K14/70521C07K14/70578C07K14/70596G01N33/57492A61K2239/31A61K2239/38A61K2239/48C07K2317/622C07K2319/02C07K2319/03G01N2333/70596
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,570,755
App. No.
18/331,859
Granted
Mar 10, 2026
Kind
B2
Abstract

Provided herein are anti-CD20 antibodies and uses thereof for treatment and diagnosis. Also provided are CD20 antigens for the production of anti-CD20 antibodies and methods of generating anti-CD20 antibodies using the CD20 antigens.

Claims (6)

1 . A canine CD20 cyclic peptide consisting of the sequence of SEQ ID NO: 20, wherein the cysteine at position 7 of SEQ ID NO: 20 forms a disulfide bond with the cysteine at position 23 of SEQ ID NO: 20, wherein the peptide further comprises a carrier protein and a peptide spacer between the canine CD20 cyclic peptide and the carrier protein.

2 . The canine CD20 cyclic peptide of claim 1 , wherein the carrier protein is KLH.

3 . The canine CD20 cyclic peptide of claim 1 , wherein the carrier protein is conjugated to a linker.

4 . The canine CD20 cyclic peptide of claim 3 , wherein the linker is a sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate linking group.

5 . The canine CD20 cyclic peptide of claim 1 , wherein the peptide spacer comprises the sequence of SEQ ID NO: 52.

6 . A method for generating an antibody that specifically binds to a canine CD20 cyclic peptide comprising the sequence of SEQ ID NO: 20, the method comprising immunizing a subject with an effective amount of the canine CD20 cyclic peptide of claim 1 .

Continuity (3)
Division 16970805
Provisional Application 62633034 · Feb 20, 2018
Related Publication 20240124602A1 · Apr 18, 2024
References Cited (26)
US 11673961B2 · Riviere et al. · 2023 [cited by applicant]
US 20040197328A1 · Young et al. · 2004 [cited by applicant]
US 20070280882A1 · Wu · 2007 [cited by applicant]
US 20110091483A1 · Beall · 2011 [cited by examiner]
US 20160220665A1 · Cobbold · 2016 [cited by examiner]
US 20230416392A1 · Riviere et al. · 2023 [cited by applicant]
JP 2016208934A2 · 2016 [cited by applicant]
WO WO2010117448A2 · 2010 [cited by applicant]
WO WO2013054127A1 · 2013 [cited by applicant]
WO WO2017011316A1 · 2017 [cited by applicant]
Almagro & Fransson,“Humanization of antibodies”, Frontiers in Bioscience 2008; 13:1619-33 (Year: 2008). [cited by applicant]
Ernst J. A. et al. “Isolation and Characterization of the B-Cell Marker CD20” Biochemistry 44: 15150 (2005)) (Year: 2005). [cited by applicant]
International Search Report and Written Opinion, PCT/US2019/018535, Memorial Sloan Kettering Cancer Center (Jul. 5, 2019). [cited by applicant]
UniProtKB Accession No. A0A026WD16_OOCBI “Glycerate kinase”, Jul. 9, 2014 (online]. [Retrieved on Jun. 17, 2019]. Retrieved from the internet: <URL:https://www.uniprot.org/uniprot/AOA026WD 16> Entire document. [cited by applicant]
UniProtKB Accession No. A0A1X4N0U5_9PROT “Glycerol-3-phosphate dehydrogenase”, Jul. 5, 2017 [online]. [Retrieved on Jun. 17, 2019]. Retrieved from the internet: <URL: https://www.uniprot.org/uniprot/AOA 1 X4N0U5> Entire… [cited by applicant]
Abaza et al., “Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (A… [cited by applicant]
Chames, et al., “Themed Section: Vector Design and Drug Delivery Review” British Journal of Pharmacology, British Journal of pharmacology, 2009 vol. 157, (14, pages). [cited by applicant]
Colman, et al., “Effects of Amino Acid Sequence Changes on Antibody-antigen Interactions” Biomolecular Research Institute, vol. 145, 1994, (4, pages). [cited by applicant]
Dudley, et al., “Adoptive-Cell-Transfer Therapy for the Treatment of Patients with Cancer,” Nature Reviews Cancer, 2003, (11, pages). [cited by applicant]
Gura, et al., “Systems for Identifying New Drugs are Often Faulty,” vol. 278, Nov. 7, 1997, (2, pages). [cited by applicant]
Jena et al., “Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor”, Blood, Aug. 19, 2010, 116(7):1035-1044. [cited by applicant]
Jena, et al., “Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor,” Blood, Aug. 19, 2010, vol. 116 No. 7, (11, pages). [cited by applicant]
Kaiser, et al., “First Pass at Cancer Genome Reveals Complex Landscape” vol. 313, Sep. 8, 2006, (1, page). [cited by applicant]
Kaiser, et al., “Reveals Complex Landscape,” Science, vol. 331, Sep. 8, 2006 (1, page). [cited by applicant]
Marincola, et al., “Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor,” Trends in Immunology, Jun. 2003, (8, pages). [cited by applicant]
Rudikoff, et al., “Single Amino Acid Substitution Altering Antigen-binding Specificity” Proc. Natl. Acad. Sci. vol. 79, Mar. 1982, (5, pages). [cited by applicant]